Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III

Clinical trial NCT05096845 · UNKNOWN

Trial details

NCT number: NCT05096845
Sponsor: Livzon Pharmaceutical Group Inc.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

COVID-19 Pandemic

Start date: 2021-08-25
Primary completion: 2022-02-08
Enrollment: 22500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.